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Oxidative stressAbstract The present study was designed to assess the relationship between anti-schistosomal
effect of the antimalarial drug meﬂoquine (Mef) and the oxidative stress status of Schistosoma man-
soni infected mice. Forty mice were divided into eight groups (5 mice/group); control (I, II), infected
(III, IV), Mef low dosage (200 mg/kg) (V, VI), and Mef high dosage (400 mg/kg) (VII, VIII). Mef
(200 and 400 mg/kg) was administered orally as a single dose at days 14 and 35 post infection (PI).
All mice were sacriﬁced after 8 weeks PI. Oral administration of Mef (200 or 400 mg/kg) at day 14
or 35 PI reduced the total worm burden by 84%, 78% and 94%, 85.7% respectively. Meanwhile,
Mef treatment reduced egg load in the intestine and the liver. Following Mef (200 and 400 mg/kg)
treatment to mice at day 14 or 35 PI, the oogram pattern showed complete disappearance of all
immature and mature ova. Treatment of mice with Mef at the two tested doses signiﬁcantly
decreased the activities of ALT, AST, ALP and GGT enzymes as compared to infected untreated
group. However, administration of Mef (200 and 400 mg/kg) at day 14 or 35 PI signiﬁcantly
(P< 0.05) decreased the MDA level and increased the levels of GSH and CAT as compared to
infected untreated group. In conclusion, Mef is an effective curative anti-schistosomal and anti-oxi-
dative drug as it alleviates the biochemical and the oxidative stress alterations. Also, Mef has schist-
osomicidal and ovicidal effects.
ª 2014 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. All rights
reserved.Introduction
Schistosomiasis is a prevalent parasitic disease in tropical and
sub-tropical areas, which accounts for the second place in
terms of socioeconomic and public health burden (Cardoso
et al., 2013; Kadry et al., 2013). Each year schistosomiasis
afﬂicts up to 600 million people in 74 tropical and sub-tropical
Meﬂoquine against Schistosoma mansoni 41countries, predominantly in the developing world (El Ridi
et al., 2014).
Schistosomiasis is associated with many complications; the
most important of these are liver damage (WHO, 2010).
Among the ﬁve different schistosome species, Schistosoma
mansoni is the most abundant one in Egypt (Helmy et al.,
2009). Pathology associated with S. mansoni results primarily
from the accumulation of parasite eggs, giving rise to hepato-
megaly that may be superseded by extensive liver ﬁbrosis
(Gryseels et al., 2006). It has also been shown that the granu-
lomatous inﬂammatory response to S. mansoni eggs entrapped
in the liver induces oxidative stress.
Oxidative stress is one of the most frequent problems in
patients with chronic liver diseases as schistosomiasis
(Heidelbaugh and Sherbondy, 2006). It was previously
reported that during schistosome infestation, the parasite tends
to switch from Krebs cycle to lactate production in the host
which results in a surplus supply of O2 which subjects the
infected host to a state of oxidative stress or increased free rad-
ical formation (Tielens, 1994). Moreover, the parasite is
exposed to ROS generated by the host effector cells as macro-
phages, eosinophils, neutrophils, and platelets (McDermott
et al., 1997). ROS leads to the release of toxic oxygen radicals
principally O2 and H2O2 during the respiratory burst. These
two radicals may interact to produce hydroxyl radical, which
is even more reactive.
Several medications are used in the treatment of schistoso-
miasis including praziquantel and oxamniquine, metrifonate,
antimonials, hycanthone and niridazole. Current treatment
relies on praziquantel (PZQ) (Zhang and Coultas, 2013).
Unfortunately, PZQ has stage-dependent susceptibility, show-
ing only poor efﬁcacy against immature schistosome stages
(Keiser et al., 2009). In addition, many lines of evidence indi-
cate to increasing the emergence of strains of S. mansoni resis-
tant to praziquantel (Zhang and Coultas, 2013). So for
controlling schistosomiasis, there is an urgent need to develop
a new effective drug.
In recent years, antimalarial drug meﬂoquine (Mef) has
been found to exhibit potential effects against schistosomes
(Xiao and Xue, 2012). The drug presented remarkable
in vitro and in vivo activities against major schistosome species
(El-Lakkany et al., 2011; Ingram et al., 2012; Zhang and Xiao,
2012). Based on the previous information, the present study
was designed to assess the relationship between anti-schisto-
somal effect of the antimalarial drug meﬂoquine and the oxi-
dative stress status of S. mansoni infected mice.
Material and methods
Drug and dose
Meﬂoquine (Larium, 250 mg tablet) was provided by F. Hoff-
mann-La Roche (Basel, Switzerland). Meﬂoquine was sus-
pended in vehicle (7% (v/v) Tween-80 and 3% (v/v) ethanol)
and administered orally as a single low dosage of 200 mg/kg
or high dosage of 400 mg/kg (Keiser et al., 2009).
Animals
Male Swiss albino mice (CD-1 strain) weighing 18–20 g were
used in all experiments. The animals were obtained from aclosed random bred colony at the Schistosome Biological Sup-
ply Center (SBSC) at Theodor Bilharz Research Institute
(TBRI), Giza, Egypt. Animals were housed in polycarbonate
boxes with steel-wire tops (not more than six animals per cage)
and bedded with wood shavings. Ambient temperature was
controlled at 22 ± 3 C with a relative humidity of
50 ± 15% and a 12-h light/dark photoperiod. Food and water
were provided ad libitum. This study was conducted in accor-
dance with legal ethical guidelines of the Medical Ethics Com-
mittee of the Theodor Bilharz Research Institute (TBRI),
Giza, Egypt (Approval No. 4018/2011).
Schistosome infection
S. mansoni cercariae (Egyptian strain) were obtained from
infected intermediate host snails (Biomphalaria alexandrina)
maintained at the SBSC. Mice were infected subcutaneously
with freshly shed 60 ± 10 cercariae/mouse (Liang et al.,
1987).
Experimental design
Forty mice were divided into eight groups (5 mice/group), as
follows: Two normal, non-infected control groups received
vehicle at days 14 and 35. Two infected non treated groups
received vehicle at days 14 and 35. Two treated groups
received a single low dosage of Mef (200 mg/kg) at days 14
and 35. Two treated groups received a single high dosage
of Mef (400 mg/kg) at days 14 and 35. Mice of all experimen-
tal groups were euthanized by exsanguination at 8 weeks
post-infection.
Study of parasitological criteria
Immediately after mice euthanization, blood was collected
from the neck blood vessels in centrifuge tubes. Hepatic and
portomesenteric vessels were perfused for worms’ recovery
and subsequent counting (Duvall and De Witt, 1967). After
perfusion, a piece of liver and the middle part of the small
intestine were used for the determination of the number of
ova per gram liver or intestinal tissues after digestion overnight
in 5% KOH (Cheever, 1968; Kamel et al., 1977). The percent-
age of eggs at various developmental stages was examined in
three samples from each mouse and the mean number of eggs
at each stage/animal was determined (Pellegrino et al., 1962).
Perfused liver, was stored at 80 C for assessing oxidative
stress parameters.
Sample preparation
Serum preparation
Blood samples collected in centrifuge tubes were centrifuged at
3000 rpm for 20 min. Serum was stored at 20 C until used
for biochemical assays.
Tissue homogenate preparation
Liver tissue was homogenized (10% w/v) in ice-cold 0.1 M
Tris–HCl buffer (pH 7.4). The homogenate was centrifuged
at 3000 rpm for 15 min. at 4 C and the resultant supernatant
was used for biochemical analysis.
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The Biodiagnostic kits (Dokki, Giza, Egypt) were used for the
determination of serum aminotransferase enzymes (AST &
ALT) activities (Reitman and Frankel, 1957), alkaline phos-
phatase (ALP) (Belﬁeld and Goldberg, 1971) and total protein
(Henry, 1964). Spectrum kit (Obour City, Cairo, Egypt) was
used for the determination of gamma-glutamyl transferase
(GGT) (Szasz et al., 1974).
Assessment of oxidative stress markers
Oxidative stress markers were detected in the resultant super-
natant of the liver homogenate. The appropriate kits (Biodiag-
nostic kits, Biodiagnostic Dokki, Giza, Egypt) were used for
the determination of malondialdehyde (MDA) (Ohkawa
et al., 1979), reduced glutathione (GSH) (Beutler et al., 1963)
and catalase (CAT) were detected according to the method
described by Aebi (1984).
Statistical analysis
All results were expressed as mean ± standard error (SE) of
ﬁve animals in each group. All data obtained were analyzed
by an ANOVA followed by Student’s t-test at 95% conﬁdence
level. Values of P< 0.05 were considered as statistically signif-
icant. All computations were performed using SPSS version
20.0 software.
Results
Effect of meﬂoquine (Mef) on parasitological parameters
The worm burden and tissue egg load in the intestine and liver
were calculated for each studied group (Tables 1 and 2). In theTable 1 Effect of meﬂoquine (Mef) administration on worm burde
Groups Time of infection Mean nu
Vehicle at day 14 13.80 ± 1
at day 35 14.00 ± 0
Mef (200 mg/kg) at day 14 2.20 ± 0
at day 35 3.00 ± 0
Mef (400 mg/kg) at day 14 0.80 ± 0
at day 35 2.00 ± 0
Values are given as mean ± SE for 5 mice in each group.
Values with different superscript letters are signiﬁcantly different (P< 0
Table 2 Effect of meﬂoquine (Mef) administration on tissue egg lo
Groups Time of infection Intestine
Vehicle at day 14 13.72 ± 2.97a
at day 35 13.63 ± 2.9a
Mef (200 mg/kg) at day 14 0.11 ± 0.11
at day 35 0.33 ± 0.18b
Mef (400 mg/kg) at day 14 0b
at day 35 0.83 ± 0.64b
Values are given as mean ± SE for 5 mice in each group.
Values with different superscript letters are signiﬁcantly different (P< 0infected control group, the total number of worms counted
was 13.80 ± 1.53 and 14.00 ± 0.95 at day 14 and 35 post
infection (PI) respectively (Table 1). Oral administration of
Mef (200 mg/kg) to mice at day 14 or 35 PI reduced the total
worm burden to 2.20 ± 0.48 (84% reduction) and 3.00 ± 0.45
(78%) whereas, administration of Mef orally (400 mg/kg) to
mice at day 14 or 35 PI reduced the total worm burden to
0.80 ± 0.58 (94% reduction) and 2.00 ± 0.71 (85.7%).
Mef treatment (200 mg/kg) at day 14 or 35 PI reduced egg
load both in the intestine (99.1%) & (97.5%) and in the liver
(97%) & (92%) respectively (Table 2) while, administration
of Mef (400 mg/kg) to mice at day 14 or 35 PI reduced egg load
both in the intestine (100%) & (93.9%) and in the liver (100%)
& (94.3%), respectively (Table 2).
Following Mef (200 and 400 mg/kg) treatment to mice at
day 14 or 35 PI, the oogram pattern showed complete disap-
pearance of all immature and mature ova (Table 3). At the
same time administration of Mef (200 and 400 mg/kg) at day
14 or 35 PI caused complete death of ova (Table 3).
Effect of meﬂoquine (Mef) on some serum biochemical
parameters
As shown in Table 4, the levels of serum ALT, AST, ALP and
GGT activities were signiﬁcantly (P< 0.05) increased in the
serum of S. mansoni infected mice as compared to normal con-
trol. Treatment of mice either with 200 or 400 mg/kg Mef at
day 14 or 35 PI signiﬁcantly (P< 0.05) decreased the activities
of studied enzymes as compared to infected untreated group.
Data recorded in Table 4 show a signiﬁcant (P< 0.05)
decrease in the serum total protein concentration following
S. mansoni infection as compared to control group. In compar-
ison with infected untreated control, serum total proteinn of S. mansoni infected mice.
mber of worms ± SE Reduction on worm burden (%)
.53a –
.95a –
.49b 84
.45b 78
.58b 94
.71b 85.7
.05).
ad of S. mansoni infected mice.
Reduction (%) Liver Reduction (%)
– 12.32 ± 1.87a –
– 13.73 ± 3.0a –
99.1 0.36 ± 0.36b 97
97.5 1.04 ± 0.48b 92
100 0b 100
93.9 0.77 ± 0.43b 94.3
.05).
Table 3 Effect of meﬂoquine (Mef) administration on oogram pattern of S. mansoni infected mice.
Groups Time of infection Oogram pattern (%ova)
Immature Mature Dead
Vehicle at day 14 74.00 ± 4.00a 23.40 ± 3.32a 2.6 ± 1.12a
at day 35 69.00 ± 4.84a 25.40 ± 4.202a 5.6 ± 1.16a
Mef (200 mg/kg) at day 14 00 ± .00b 00 ± .00b 100 ± .00b
at day 35 00 ± .00b 00 ± .00b 100 ± .00b
Mef (400 mg/kg) at day 14 00 ± .00b 00 ± .00b 100 ± .00b
at day 35 00 ± .00b 00 ± .00b 100 ± .00b
Values are given as mean ± SE for 5 mice in each group.
Values with different superscript letters are signiﬁcantly different (P< 0.05).
Table 4 Effect of meﬂoquine (Mef) administration on some serum biochemical parameters of S. mansoni infected mice.
Parameter Time of infection Control Infected
– Mef (200 mg/kg) Mef (200 mg/kg)
ALT at day 14 29.78 ± 1.90a 57.09 ± 0.69d 29.57 ± 1.66a 25.686 ± 1.35a
at day 35 28.55 ± 1.33a 54.06 ± 1.94d 45.06 ± 0.73c 38.91 ± 0.17b
AST at day 14 47.74 ± 0.37a 130.25 ± 2.92e 63.062 ± 3.63b 56.05 ± 2.38a,b
at day 35 48.27 ± 0.13a 110.62 ± 3.90d 64.5 ± 8.68b 78.5 ± 2.71c
ALP at day 14 8.70 ± 1.18a 49.00 ± 0.632c 10.65 ± 1.059a,b 10.78 ± 0.61a,b
at day 35 8.82 ± 0.807a 48.332 ± 1.27c 12.34 ± 1.31a,b 13.332 ± 3.06b
GGT at day 14 2.17 ± 0.38a 17.08 ± 1.179d 3.83 ± 0.57a,b,c 4.29 ± 0.42a,b,c
at day 35 2.46 ± 0.38a,b 20.59 ± 1.34e 4.77 ± 0.38b,c 5.57 ± 0.95c
Total protein at day 14 6.695 ± 0.138b 5.615 ± 0.145a 5.792 ± 0.096a 5.69 ± 0.30a
at day 35 6.92 ± 0.065b 5.47 ± 0.17a 6.43 ± 0.30b 6.66 ± 0.133b
Values are given as mean ± SE for 5 mice in each group.
Values with different superscript letters are signiﬁcantly different (P< 0.05).
Meﬂoquine against Schistosoma mansoni 43concentration of mice administered Mef at the two tested doses
at day 35 PI revealed a signiﬁcant increase (P< 0.05).
Effect of meﬂoquine (Mef) on oxidative status of the S. mansoni
infected mice
The obtained results showed signiﬁcant induction (P< 0.05)
in the hepatic MDA level after infection of S. mansoni as com-
pared to control group (Fig. 1). However, administration of
Mef at the two tested doses at day 14 or 35 PI signiﬁcantly
(P< 0.05) decreased the level of MDA as compared to the
corresponding infected untreated group.
As shown in Fig. 2, GSH content was signiﬁcantly
(P< 0.05) decreased in the hepatic tissues of S. mansoni
infected mice as compared to normal control. Treatment of
mice either with 200 or 400 mg/kg Mef at day 14 or 35 day
PI signiﬁcantly (P< 0.05) increased the level of GSH as com-
pared to corresponding infected untreated group.
Data illustrated in Fig. 3, show that CAT activity was sig-
niﬁcantly (P< 0.05) decreased in the hepatic tissues of S. man-
soni infected mice as compared to normal control. However,
the administration of Mef at the two tested doses at day 14
or 35 PI signiﬁcantly (P< 0.05) increased the level of CAT
as compared to the corresponding infected untreated group.Discussion
Schistosomiasis is a neglected tropical disease, endemic in 76
countries, that afﬂicts more than 240 million people (Santos
et al., 2014). There is no vaccine for schistosomiasis, and che-
motherapy relies heavily on a single drug, praziquantel
(Patocka et al., 2014), although PZQ is a very efﬁcacious
and safe antischistosomal drug, it has some disadvantages, as
stage-dependent susceptibility and poor efﬁcacy against imma-
ture schistosome stages (Ingram et al., 2012). Therefore, there
is an urgent need to develop a new antischistosomal drug. The
antimalarial drug meﬂoquine (Mef) possesses interesting antis-
chistosomal properties (El-Lakkany et al., 2011; Xiao, 2013).
The treatment was recommended in several studies as it pro-
vided many complementary goals, a reduction of egg-induced
pathology, minimal parenchymal changes and the eradication
of worms (El-Lakkany et al., 2011). Previous studies focused
their studies on the epidemiology of schistosomiasis or the
physiology of the parasites neglecting to some extent the met-
abolic changes developed in the host in consequence to infec-
tion or Mef treatment. Therefore, the assessment of Mef
treatment efﬁcacy in infected mice is important for the evalu-
ation of the magnitude of infection and efﬁcacy of the
treatment.
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Figure 1 Effect of meﬂoquine (Mef) administration on liver MDA level of S. mansoni infected mice. Values are given as mean ± SE for
5 mice in each group. Values with different superscript letters are signiﬁcantly different (P< 0.05).
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Figure 2 Effect of meﬂoquine (Mef) administration on liver GSH level of S. mansoni infected mice. Values are given as mean ± SE for 5
mice in each group. Values with different superscript letters are signiﬁcantly different (P< 0.05).
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a single low dosage (200 mg/kg) or single high dosage (400 mg/
kg) for juvenile and adult stages signiﬁcantly decreased the
worm burden, tissue egg load, number of immature egg stages
and number of mature eggs with the complete death of eggs.
These results are in agreement with the reports of El-
Lakkany et al. (2011) and Abdel-Fattah and Ahmed (2011).
In consonance with the report of Rabia et al. (2010), the death
of worms following Mef treatment may be attributed to meta-
bolic disorders, mechanical destruction and muscular contrac-
tion of the treated worms. Moreover, percent reduction in the
egg count in the infected groups treated with Mef was found to
be higher in the intestinal tissue than in hepatic tissue. This
variation was attributed to excretion of some ova from the
intestine prior to digestion and to hepatic shift of worms aftertreatment (Abdel-Ghaffar, 2004; Zhang et al., 2009; Rabia
et al., 2010).
Determination of enzyme levels, such as serum AST and
ALT is largely used during the assessment of liver damage
by schistosomal infection (Aly and Mantawy, 2013; Al-Sayed
et al., 2014). Necrosis or membrane damage releases the
enzymes into circulation; therefore, they can be measured in
the serum. In agreement with the reports of Kadry et al.
(2013) and Mahmoud and Elbessoumy (2013), the increment
of such enzymes in serum may be due to the destruction of
hepatocytes by the action of toxins of the parasite eggs leading
to their release into the circulation. In addition, Naik et al.
(2011) reported that hepatocyte membrane damage seems to
be the prime culprit for the marked increase in the serum mar-
ker enzymes, AST, ALT, and ALP following schistosomal
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Figure 3 Effect of meﬂoquine (Mef) administration on liver CAT activity of S. mansoni infected mice. Values are given as mean ± SE
for 5 mice in each group. Values with different superscript letters are signiﬁcantly different (P< 0.05).
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(2011) and Abdel-Fattah and Ahmed (2011), data from the
present study showed that treatment with Mef at the two tested
doses for juvenile and adult stages signiﬁcantly decreased the
levels of serum AST, ALT, ALP and GGT activities in
infected-treated group indicating maintenance of functional
integrity of hepatic cell membrane. The anti-schistosomal
drug, Mef causes worm tegument damage that consequently
limits or enhances signiﬁcantly immune response of patients
and generates a reversion of the level of ﬁbrosis (Xiao et al.,
2010). Thereby as evidenced by several studies the signiﬁcant
reduction in oxidative stress initiates a positive impact on the
preservation of the liver integrity and function.
The major cause of metabolic dysfunction during patho-
genesis is the site speciﬁc oxidative damage of some of the sus-
ceptible amino acids of protein (Bandopadhyay et al., 1999). In
accord with the studies of El-Emam et al. (2011), El-Lakkany
et al. (2011) and Abdel-Fattah and Ahmed (2011) the present
study showed that S. mansoni infection in mice induced a sig-
niﬁcant decrease in the serum total protein. In consonance
with the report of El-Lakkany et al. (2011) and Abdel-
Fattah and Ahmed (2011), data from the present study showed
that treatment with Mef at the two tested doses for juvenile
and adult stages signiﬁcantly increased the level of total pro-
tein activities in infected-treated group.
Schistosomiasis is associated with the liberation of free rad-
icals and disturbance in the cellular antioxidant system. As the
infection becomes established, the parasite comes under oxida-
tive stress generated by the host immune system which is coun-
teracted by the parasite antioxidant defense mechanism
(Aragon et al., 2008). The generation of oxygen-derived free
radicals may be an initial, nonspeciﬁc defense reaction of the
host toward parasitic infection. In the present study, elevation
in the level of the end product of lipid peroxidation, malondi-
aldehyde (MDA) in the liver of control group was observed in
schistosome infected mice. The increased MDA level suggests
enhanced lipid peroxidation leading to tissue damage and fail-
ure of antioxidant defense mechanisms to prevent formation of
excessive free radicals (Mahmoud and Elbessoumy, 2013;Kadry et al., 2013). Moreover, decreasing the antioxidant
capacity of the liver, leads to the generation of lipid peroxides
that may play a major role in the pathology associated with
schistosomiasis (Cunha et al., 2012). Soliman et al. (2000)
and Mantawy et al. (2011) reported that oxidative stress due
to schistosomiasis causes an elevation in lipid peroxides, since
the complex mechanism of lipid peroxidation is known to
require the participation of highly reactive oxygen and other
reactive oxygen metabolites in the chain of biochemical reac-
tions, thus whenever these free radicals are involved, lipid per-
oxides are in turn increased. Treatment with Mef at the two
tested doses in the present study signiﬁcantly decreases the
MDA level, suggesting that the mechanism of Mef hepatopro-
tection may be due to its antioxidant effect.
Reduced glutathione (GSH) is an intracellular reductant
and plays a major role in catalysis, metabolism and transport.
It protects cells against free radicals, peroxides and other toxic
compounds (Hiraishi et al., 1994). It has been reported that
schistosomiasis caused an impairment of the liver GSH con-
tent of mice, thus serving to decrease the antioxidant capacity
of the liver and leading to the generation of lipid peroxides that
may in turn play a central role in the pathology associated with
schistosomiasis (Cunha et al., 2012). The present study
revealed that the content of reduced glutathione was signiﬁ-
cantly (P< 0.5) decreased in hepatic tissue of infected non
treated mice group compared to control group. These results
are in agreement with the reports of Mahmoud and
Elbessoumy (2013) and Kadry et al. (2013). Accordingly,
Hamed (2006) found that glutathione level decreased after par-
asitic infection and Gharib et al. (1999) attributed the
decreased level of glutathione to the increased cytotoxicity
with H2O2 which is produced as a result of inhibition of gluta-
thione reductase that keeps glutathione in its reduced form.
The present study showed that administration of Mef by the
two tested doses at days 14 and 35 PI caused a signiﬁcant
(P< 0.05) increase in the content of reduced glutathione com-
pared with infected non-treated groups.
Catalase (CAT) is a key component of the antioxidant
defense system. The antioxidant enzyme catalase plays an
46 S.R. Fahmy et al.important role in keeping homeostasis and protection against
oxidative damage by removing the toxic free radicals in vivo
(EI-Shenawy et al., 2008; Jia et al., 2009). The present data
demonstrated that the activity of the liver tissue CAT of the
infected non treated mice signiﬁcantly decreased as compared
to control group. In conjunction with the report of Rizk
et al. (2012) the reduction in catalase activity could be attrib-
uted to its utilization in scavenging the free radicals’ overload
which generated during schistosomiasis. Moreover, the
reduced antioxidant production was due to increased oxygen
metabolites causing a decrease in the activity of antioxidant
defense system. Treatment of the infected mice with Mef signif-
icantly increased the activity of the liver tissue CAT as com-
pared to that of the infected mice.
The exact mechanism of antioxidant activity of Mef is not
clear. Meﬂoquine is a quinoline methanol, which is structurally
related to quinine. The antioxidant effect of the meﬂoquine
could be explained by the stimulation of the antioxidant
enzymes or the inhibition of lipid peroxidation. Thus,
Tapiwanashe et al. (1997), indicate in their work, that the
injection of 20 mg/kg of Chloroquine to rats is followed by
an increase in the activity of SOD and CAT enzymes. More-
over, the antioxidant action of meﬂoquine, may be due to
the inhibition of the enzyme xanthine oxidase responsible for
the formation of free radicals in particular the anion superox-
ide O2 (Laszlo et al., 1993). In conclusion, Mef is an effective
curative anti-schistosomal and anti-oxidative drug as it allevi-
ates the biochemical and the oxidative stress alterations. Also,
Mef has schistosomicidal and ovicidal effects.References
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